At the 28th Conference of the European Wound Management Association, BSN medical, the global provider of integrated therapy solutions, will present its comprehensive concept for the management of venous leg ulcers in Kraków, Poland, on 9–11 May.

BSN medical is a ‘corporate A sponsor’ of the European Wound Management Association (EWMA) and its annual congress, which sees the company fund ten educational grants for EWMA participants. In compliance with MedTech Europe’s ‘Code of Ethical Business Practice’, BSN medical is one of the first industry partners to support these grants, allowing healthcare professionals to attend the conference. The selection process is solely governed by EWMA.

At booth W408, BSN medical will display and discuss the concept of venous leg ulcer management, with a focus on three topics: wound bed preparation, exudate management and oedema management.

BSN medical will also hold a symposium titled ‘The Management of Venous Leg Ulcers (VLUs) – The value of highquality care’ in the Wisla room on 10 May at 1-2pm, where the following experts will be speaking:

  • Dr Karl-Christian Münter, a GP and phlebologist from Hamburg, Germany, will focus on compression therapy, particularly rationale, established methods and new developments.
  • Vascular nurse specialist Dr Leanne Atkin, from The Mid Yorkshire Hospitals NHS Trust in Wakefield, the UK, will discuss the true impact of highly exuding ulcers.
  • Professor Dr Matthias Augustin, director of the Institute of Healthcare Research in Dermatology and Nursing at Universität Hamburg, will highlight ten essential steps for improving quality of care for VLUs in practice.

All speakers from the BSN medical symposium will be present at the company’s booth after the session at 2:15-2:45pm, allowing delegates to expand on questions raised during the lectures.

Practical hands-on workshops

The BSN team will showcase patient-tailored approaches that combine infection and exudate management with the Cutimed Sorbact, Cutimed Siltec and Cutimed Sorbion solutions. BSN medical will display its full range of therapy solutions that assist with wound bed preparation, exudate and infection management for VLUs. Hands-on demonstrations of the Cutimed wound-care range will be combined with the application of JOBST compression stockings and compression bandaging for oedema management. Visit the BSN exhibition stand to meet experts, test products and discover the latest information about the full continuum of care in wound management.

"We are proud that we will again present true innovation for the management of chronic and acute wounds at EWMA. With our focus on patients, BSN medical is offering integrated therapeutic solutions, covering all aspects of wound management to provide an optimal environment for wound healing," says Karsten Hemmrich, vice-president global marketing and innovation at BSN’s parent company Essity. "Our ambition is to not only provide solutions for healthcare professionals, but also to improve the patient’s quality of life. BSN medical, as part of Essity, is one of the few wound-care companies that can offer a very broad portfolio of products and solutions, thereby providing a truly comprehensive and holistic treatment approach."

Broad portfolio of products

BSN medical is a global leader in wound care and related vascular diseases, lymphology and non-invasive orthopedic products. BSN aims to provide an integrated therapy-driven approach with its broad portfolio of products, which are enhanced by insights into current therapeutic areas and are complemented by a progressive approach to partnerships.

Its well-known brands, including Leukoplast, Cutimed, JOBST, Delta-Cast and Actimove, are among the most trusted in the healthcare market. With its comprehensive product portfolio, BSN medical addresses patient needs in the most varied conditions in wound care, vascular diseases and orthopedic treatments.

BSN medical was acquired by Essity (formerly known as SCA) in April 2017.

Hygiene and health

Essity is a leading global hygiene and health company dedicated to improving well-being through its products and solutions that are essentials for everyday life. The name Essity stems from the words ‘essentials’ and ‘necessities’. The company’s sustainable business model creates value for people and nature. Sales are conducted in approximately 150 countries under the leading global brands TENA and Tork, and other strong brands, such as Jobst, Leukoplast, Libero, Libresse, Lotus, Nosotras, Saba, Tempo, Vinda and Zewa. Essity has about 48,000 employees. In 2017, its net sales amounted to approximately €11.3 billion. The headquarters is located in Stockholm, Sweden, and the company is listed on Nasdaq Stockholm.